-
公开(公告)号：US06326523B1
公开(公告)日：2001-12-04
申请号：US09536582
申请日：2000-03-28
IPC分类号： C07C5327
CPC分类号： C07C5/42
摘要： Process for the dehydrogenation of a hydrocarbon feed comprising a step of dehydrogenating the hydrocarbon feed and a step of removing hydrogen being formed by dehydrogenation reactions, wherein the dehydrogenation and hydrogen removal steps are performed simultaneously in presence of a dehydrogenation catalyst being combined with a metal compound being reduced in presence of hydrogen.
摘要翻译： 烃原料脱氢的方法，包括使烃进料脱氢的步骤和除去由脱氢反应形成的氢的步骤，其中脱氢和除氢步骤在脱氢催化剂与金属化合物组合的存在下同时进行 在氢存在下还原。
-
公开(公告)号：US5238945A
公开(公告)日：1993-08-24
申请号：US876040
申请日：1992-04-30
申请人： Jens Perregaard , Torben Skarsfeldt
发明人： Jens Perregaard , Torben Skarsfeldt
IPC分类号： A61K31/445
CPC分类号： A61K31/445
摘要： Disclosed is a method of treating psychoses in human beings, comprising the step of administering an effective amount of the compound, ##STR1## or a pharmaceutically acceptable salt thereof, to a patient in need thereof.Said compound selectively blocks dopamine neurones in the ventral tegmental area of the brain, substantially without blocking the dopamine neurones in the substantia nigra pars compacta and, therefore, is free from the extrapyramidal side effects of common neuroleptics.
摘要翻译： 公开了一种治疗人类精神病的方法，包括向有需要的患者施用有效量的化合物“IMAGE”或其药学上可接受的盐的步骤。 所述化合物选择性地阻断脑的腹侧被盖区域中的多巴胺神经元，基本上不阻塞黑质微结构中的多巴胺神经元，因此没有普通神经安定药物的锥体束外副作用。
-
公开(公告)号：US07087801B2
公开(公告)日：2006-08-08
申请号：US10686680
申请日：2003-10-17
申请人： Jens Perregaard , Gregory Patience
发明人： Jens Perregaard , Gregory Patience
IPC分类号： C07C5/333
CPC分类号： C07C5/46 , B01J8/009 , B01J8/0285 , B01J8/067 , B01J8/1836 , B01J19/2475 , B01J21/10 , B01J23/002 , B01J23/22 , B01J27/198 , B01J35/065 , B01J2208/00132 , B01J2208/0015 , B01J2208/00309 , B01J2208/00522 , B01J2523/00 , C07C51/215 , Y02P20/52 , C07C11/06 , C07C57/145 , B01J2523/51 , B01J2523/55
摘要： A reactor system for oxidative conversion of hydrocarbons comprising at least one reactor tube being provided with a plurality of perforations along a wall of the tube and a reaction zone with an active catalyst arranged on tube side and/or shell side of the reactor tube; anda bed of particulates material surrounding the at least one reactor tube, the bed of particulate material being adapted to be fluidised by an oxygen containing atmosphere and to transport heat from the reactor tube.
摘要翻译： 一种用于烃的氧化转化的反应器系统，包括至少一个反应器管，沿着管的壁设置有多个穿孔，反应区具有布置在反应器管的管侧和/或壳侧上的活性催化剂; 以及围绕所述至少一个反应器管的微粒材料床，所述颗粒材料床适于由含氧气氛流化并且从所述反应器管输送热量。
-
4.发明授权Fused benzo compounds for the treatment of central nervous system disorders 失效用于治疗中枢神经系统疾病的稠合苯并噻唑化合物
公开(公告)号：US6140331A
公开(公告)日：2000-10-31
申请号：US998245
申请日：1997-12-24
IPC分类号： C07D233/32 , A61K31/335 , A61K31/34 , A61K31/343 , A61K31/357 , A61K31/36 , A61K31/4427 , A61K31/495 , A61K31/496 , A61P9/00 , A61P9/10 , A61P25/18 , A61P25/20 , A61P25/28 , C07D233/36 , C07D307/79 , C07D307/83 , C07D317/46 , C07D319/16 , C07D319/18 , C07D403/12 , C07D405/02 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D417/02 , C07D417/12 , C07D417/14 , A61K31/445
CPC分类号： C07D307/79 , C07D233/36 , C07D319/18 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12
摘要： ##STR1## Fused benzo compounds of formula (I), wherein A is a 2 to 6 membered hydrocarbon spacer group, B is a polar divalent group selected from SO, SO
2 , and a group (a); U is C, N or CH; X is a divalent 3-4 membered chain optionally comprising one or more heteroatoms; R
1 is an aliphatic hydrocarbon group, arylalkyl or diphenylalkyl; R
2 and R
3 are hydrogen or alkyl or together form an ethylene or propylene bridge; R
4 , R
5 and R
6 are hydrogen or substituents; R
7 and R
8 are hydrogen or substituents including, a group --COOR
9 and a group --CONR
10 R
11 ; are 5-HT
1A receptor ligands useful in the treatment of CNS disorders. Pharmaceutical compositions comprising the compounds and their use for the manufacture of a pharmaceutical preparation are also disclosed.摘要翻译： 式（I）的稠合苯并
化合物，其中A是2至6元烃间隔基，B是选自SO，SO 2和（a）组的极性二价基团。 U是C，N或CH; X是任选包含一个或多个杂原子的二价3-4元链; R1是脂族烃基，芳基烷基或二苯基烷基; R2和R3是氢或烷基或一起形成乙烯或丙烯桥; R4，R5和R6是氢或取代基; R7和R8是氢或取代基，包括-COOR9和基团-CONR10R11; 是可用于治疗CNS疾病的5-HT 1A受体配体。 还公开了包含该化合物的药物组合物及其制备药物制剂的用途。-
公开(公告)号：US06881759B2
公开(公告)日：2005-04-19
申请号：US10806443
申请日：2004-03-23
IPC分类号： C07C29/152 , C07B61/00 , C07C29/151 , C07C31/04 , C07C27/00
CPC分类号： C07C29/1512 , Y02P20/52 , C07C31/04
摘要： The present invention is a novel process for methanol production in a liquid phase reactor from a synthesis gas comprising of hydrogen, carbon dioxide and carbon monoxide. The liquid phase reactor contains a solid catalyst suspended in methanol. In this innovation, methanol acts both as a product and as a suspension medium for the catalyst. The new innovation exploits the condensing conditions for methanol production. By operating at condensing conditions, the methanol partial pressure at equilibrium is higher than the boiling pressure of methanol at the given temperature. Hence the produced methanol of the equilibrium composition condenses creating the potential of more gas to be converted. Since equilibrium is not a limiting factor, high conversions can be obtained.
摘要翻译： 本发明是由氢，二氧化碳和一氧化碳组成的合成气体在液相反应器中生产甲醇的新方法。 液相反应器含有悬浮在甲醇中的固体催化剂。 在这项创新中，甲醇既作为产品又作为催化剂的悬浮介质。 新的创新利用甲醇生产的冷凝条件。 通过在冷凝条件下操作，平衡时的甲醇分压高于在给定温度下甲醇的沸腾压力。 因此，产生的平衡组合物的甲醇会凝结，从而产生更多的待转化气体的潜力。 由于平衡不是限制因素，因此可以获得高转化率。
-
公开(公告)号：US5830896A
公开(公告)日：1998-11-03
申请号：US484361
申请日：1995-06-07
IPC分类号： C07D295/06 , A61K31/44 , A61K31/445 , A61K31/451 , A61K31/495 , A61K31/496 , A61P9/00 , A61P21/00 , A61P25/00 , A61P25/02 , A61P25/08 , A61P25/18 , A61P25/20 , A61P25/26 , A61P25/28 , C07D20060101 , C07D211/08 , C07D211/14 , C07D211/18 , C07D211/20 , C07D211/44 , C07D211/54 , C07D211/70 , C07D211/72 , C07D211/74 , C07D213/04 , C07D221/20 , C07D241/02 , C07D241/04 , C07D241/06 , C07D295/073 , C07D295/13 , C07D295/135 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D491/10 , C07D491/20 , C07D295/00
CPC分类号： C07D295/135 , C07D211/18 , C07D295/13 , C07D491/10
摘要： This subject invention relates to dimeric 4-phenylpiperidine, 4-phenyl-1,2,3,6-tetrahydropyridine, or 4-phenylpiperazine compounds or dimeric spirocyclic piperidine compounds having general formula (1), ##STR1## wherein n is 1-5; R.sup.1 to R.sup.4 are substituents; R.sup.5 and R.sup.6 each hydrogen or alkyl or form together an ethylene or propylene bridge; X is O, S, SO, SO.sub.2, CO or (CH.sub.2).sub.m, m being 0 or 1, X is NR.sup.7, R.sup.7 being H, alkyl, cycloalkyl, cycloalkylalkyl, phenyl, or phenylalklyl, or X is CR.sup.8--R.sup.9, wherein R.sup.8 and R.sup.9 are selected from hydroxy and the substituents defined under R.sup.7 ; and (i) Z.sup.1 is a substituent and Z.sup.2 is (CH.sub.2).sub.p wherein p is 0; and Y is N, C or CH; (ii) Z.sup.1 and Y are linked together via a single bond, thereby forming a spirocyclic junction; in which case Y is C; Z.sup.1 is O, S, (CH.sub.2).sub.q, q being 1, 2 or 3, or Z.sup.1 is CH.sub.2 O, CH.sub.2 S, CH.sub.2 CH.sub.2 O, CH.sub.2 CH.sub.2 S, CH.dbd.CH, CH.dbd.CHCH.sub.2, CH.sub.2 OCH.sub.2, CH.sub.2 SCH.sub.2, CH.dbd.CH--O, or CH.dbd.CH--S; and Z.sup.2 is O, S or (CH.sub.2).sub.p, p being 0 or 1; are potent sigma receptor ligands thus being useful as drugs for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile demential of the Alzheimer tpe or Parkinson's disease.
摘要翻译： 本发明涉及具有通式（1）的二聚4-苯基哌啶，4-苯基-1,2,3,6-四氢吡啶或4-苯基哌嗪化合物或二聚螺环哌啶化合物，其中 n为1-5; R1至R4是取代基; R5和R6各自为氢或烷基或一起形成乙烯或丙烯桥; X是O，S，SO，SO2，CO或（CH2）m，m是0或1，X是NR7，R7是H，烷基，环烷基，环烷基烷基，苯基或苯基烷基，或X是CR8-R9，其中 R8和R9选自羟基和R7定义的取代基; 和（i）Z1是取代基，Z2是（CH2）p，其中p是0; Y为N，C或CH; （ii）Z1和Y通过单键连接在一起，从而形成螺环结; 在这种情况下，Y是C; Z1是O，S，（CH2）q，q是1,2或3，或Z1是CH2O，CH2S，CH2CH2O，CH2CH2S，CH = CH，CH = CHCH2，CH2OCH2，CH2SCH2，CH = CH-O或CH = CH-S; Z2为O，S或（CH2）p，p为0或1; 是有效的西格玛受体配体，因此可用作治疗焦虑，精神病，癫痫，惊厥，运动障碍，运动障碍，遗忘症，脑血管疾病，阿尔茨海默病或帕金森病老年痴呆症的药物。
-
公开(公告)号：US5684012A
公开(公告)日：1997-11-04
申请号：US486740
申请日：1995-06-07
IPC分类号： C07D295/06 , A61K31/44 , A61K31/445 , A61K31/451 , A61K31/495 , A61K31/496 , A61P9/00 , A61P21/00 , A61P25/00 , A61P25/02 , A61P25/08 , A61P25/18 , A61P25/20 , A61P25/26 , A61P25/28 , C07D20060101 , C07D211/08 , C07D211/14 , C07D211/18 , C07D211/20 , C07D211/44 , C07D211/54 , C07D211/70 , C07D211/72 , C07D211/74 , C07D213/04 , C07D221/20 , C07D241/02 , C07D241/04 , C07D241/06 , C07D295/073 , C07D295/13 , C07D295/135 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D491/10 , C07D491/20
CPC分类号： C07D295/135 , C07D211/18 , C07D295/13 , C07D491/10
摘要： This subject invention relates to dimeric 4-phenylpiperidine, 4-phenyl-1,2,3,6-tetrahydropyridine, or 4-phenylpiperazine compounds or dimeric spirocyclic piperidine compounds having general formula (I), ##STR1## wherein n is 1-5; R.sup.1 to R.sup.4 are substituents; R.sup.5 and R.sup.6 each hydrogen or alkyl or form together an ethylene or propylene bridge; X is O, S, SO, SO.sub.2, CO or (CH.sub.2).sub.m, being 0 or 1, X is NR.sup.7, R.sup.7 being H, alkyl, cycloalkyl, cycloalkylalkyl, phenyl, or phenylalkyl, or X is CR.sup.8 R.sup.9, wherein R.sup.8 and R.sup.9 are selected from hydroxy and the substituents defined under R.sup.7 ; and (i) Z.sup.1 is a substituent and Z.sup.2 is (CH.sub.2).sub.p wherein p is 0; and Y is N, C or CH; (ii) Z.sup.1 and Y are linked together via a single bond, thereby forming a spirocyclic junction; in which case Y is C; Z.sup.1 is O, S, (CH.sub.2).sub.q, q being 1, 2 or 3, or Z.sup.1 is CH.sub.2 O, CH.sub.2 S, CH.sub.2 CH.sub.2 O, CH.sub.2 CH.sub.2 S, CH.dbd.CH, CH.dbd.CHCH.sub.2, CH.sub.2 OCH.sub.2, CH.sub.2 SCH.sub.2, CH.dbd.CH--O, or CH.dbd.CH--S; and Z.sup.2 is O, S or (CH.sub.2).sub.p, p being 0 or 1; are potent sigma receptor ligands thus being useful as drags for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile demential of the Alzheimer type or Parkinson's disease.
摘要翻译： 本发明涉及具有通式（I）的二聚4-苯基哌啶，4-苯基-1,2,3,6-四氢吡啶或4-苯基哌嗪化合物或二聚螺环哌啶化合物，其中 n为1-5; R1至R4是取代基; R5和R6各自为氢或烷基或一起形成乙烯或丙烯桥; X是O，S，SO，SO 2，CO或（CH 2）m，是0或1，X是NR 7，R 7是H，烷基，环烷基，环烷基烷基，苯基或苯基烷基，或X是CR 8 R 9，其中R 8和 R9选自羟基和R7定义的取代基; 和（i）Z1是取代基，Z2是（CH2）p，其中p是0; Y为N，C或CH; （ii）Z1和Y通过单键连接在一起，从而形成螺环结; 在这种情况下，Y是C; Z1是O，S，（CH2）q，q是1,2或3，或Z1是CH2O，CH2S，CH2CH2O，CH2CH2S，CH = CH，CH = CHCH2，CH2OCH2，CH2SCH2，CH = CH-O或CH = CH-S; Z2为O，S或（CH2）p，p为0或1; 是有效的西格玛受体配体，因此可用作治疗焦虑，精神病，癫痫，惊厥，运动障碍，运动障碍，遗忘症，脑血管疾病，阿尔茨海默氏型老年痴呆症或帕金森病的药物。
-
公开(公告)号：US06515146B1
公开(公告)日：2003-02-04
申请号：US09654299
申请日：2000-09-01
申请人： Jens Perregaard , Jesus Santamaria , Miquel Menendes , Reyes Mallada , Gregory Patience , Julian R. H. Ross , Erzeng Xue , Jean-Claude Volta , Anne Julbe , David Furrusseng
发明人： Jens Perregaard , Jesus Santamaria , Miquel Menendes , Reyes Mallada , Gregory Patience , Julian R. H. Ross , Erzeng Xue , Jean-Claude Volta , Anne Julbe , David Furrusseng
IPC分类号： C07D30760
CPC分类号： C07C5/46 , B01J8/009 , B01J8/0285 , B01J8/067 , B01J8/1836 , B01J19/2475 , B01J21/10 , B01J23/002 , B01J23/22 , B01J27/198 , B01J35/065 , B01J2208/00132 , B01J2208/0015 , B01J2208/00309 , B01J2208/00522 , B01J2523/00 , C07C51/215 , Y02P20/52 , C07C11/06 , C07C57/145 , B01J2523/51 , B01J2523/55
摘要： Process for the oxidation of a hydrocarbon substrate to a corresponding oxidised hydrocarbon compound by contacting the hydrocarbon substrate with an oxygen containing atmosphere in presence of a catalyst being active in the oxidation of the hydrocarbon substrate, which process comprises the steps of: passing a process gas containing the hydrocarbon substrate through a reaction zone with the catalyst; introducing the oxygen containing atmosphere divided into a plurality of substreams successively into the reaction zone; within the reaction zone reacting the process gas continuously with the oxygen containing atmosphere; and withdrawing from the reaction zone a product gas containing oxidised hydrocarbon compound and carbon monoxide.
摘要翻译： 通过使烃底物与含氧气氛在催化剂存在下在烃基底氧化反应的存在下接触将烃底物氧化成相应的氧化烃化合物的方法，该方法包括以下步骤：使工艺气体 通过与催化剂的反应区含有烃基质; 将分成多个子流的含氧气氛依次引入反应区; 在反应区内连续地与含氧气氛反应工艺气体; 并从反应区抽出含有氧化烃化合物和一氧化碳的产物气体。
-
公开(公告)号：US5972964A
公开(公告)日：1999-10-26
申请号：US955376
申请日：1997-10-22
申请人： Jens Perregaard
发明人： Jens Perregaard
IPC分类号： C07D295/12 , A61K31/136 , A61K31/34 , A61K31/343 , A61K31/38 , A61K31/381 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/415 , A61K31/4166 , A61K31/445 , A61K31/495 , A61P9/00 , A61P9/10 , A61P25/00 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/26 , A61P25/30 , C07C211/58 , C07C211/60 , C07C233/15 , C07C233/43 , C07C233/80 , C07C255/58 , C07C275/26 , C07C275/28 , C07C275/40 , C07C311/05 , C07C311/08 , C07C311/21 , C07C327/22 , C07C327/26 , C07D209/14 , C07D233/32 , C07D233/36 , C07D307/81 , C07D333/58 , C07D405/06 , C07D405/12 , C07D409/12
CPC分类号： C07D233/32 , C07C211/60 , C07C233/43 , C07C233/80 , C07C275/40 , C07C311/08 , C07D209/14 , C07D307/81 , C07D333/58 , C07C2101/08 , C07C2101/14 , C07C2102/08
摘要： Compounds of formula I ##STR1## wherein R1.dbd.(cyclo)alk(en)yl, aralkyl, alkyl(oxy)carbonyl, CONH2, etc.; R2.dbd.H, (cyclo)alk(en)yl, aralkyl, etc.; R3-R5.dbd.H, halo, alkyl, alkoxy, etc.; R6,R7.dbd.H, alkyl; R6R7.dbd.atoms to complete a ring; R8,R9.dbd.groups cited for R2, 2-oxoimidazolidinoalkyl, etc.; NR8R9=heterocyclyl; 1 of X,Y=CH2 and the other.dbd.CH2, O, S were prepd. Thus, 1-indancarboxylic acid was converted in 5 steps to 1-(N,N-dipropylaminomethyl)-6-formylaminoindane oxalate which had ED50 of 0.0055.mu.M/kg s.c. in the 8--OH DPAT cue agonism test in rats.
摘要翻译： 式Ⅰ化合物，其中R1 =（环）烷（烯）基，芳烷基，烷基（氧基）羰基，CONH2等; R2 = H，（环）烷（en）基，芳烷基等; R3-R5 = H，卤素，烷基，烷氧基等; R6，R7 = H，烷基; R6R7 =原子完成环; R8，R9 = R2，2-氧代咪唑烷基烷基等引用的基团; NR8R9 =杂环基; 1的X，Y = CH 2，另一个= CH 2，O，S。 因此，将1-二氢化茚羧酸按5分钟转化为ED50为0.0055.mu.M / kg·s的1-（N，N-二丙基氨基甲基）-6-甲酰氨基茚满草酸盐。 在大鼠的8-OH DPAT提示激动试验中。
-
公开(公告)号：US5837707A
公开(公告)日：1998-11-17
申请号：US467760
申请日：1995-06-06
IPC分类号： C07D295/06 , A61K31/44 , A61K31/445 , A61K31/451 , A61K31/495 , A61K31/496 , A61P9/00 , A61P21/00 , A61P25/00 , A61P25/02 , A61P25/08 , A61P25/18 , A61P25/20 , A61P25/26 , A61P25/28 , C07D20060101 , C07D211/08 , C07D211/14 , C07D211/18 , C07D211/20 , C07D211/44 , C07D211/54 , C07D211/70 , C07D211/72 , C07D211/74 , C07D213/04 , C07D221/20 , C07D241/02 , C07D241/04 , C07D241/06 , C07D295/073 , C07D295/13 , C07D295/135 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D491/10 , C07D491/20
CPC分类号： C07D295/135 , C07D211/18 , C07D295/13 , C07D491/10
摘要： This subject invention relates to dimeric 4-phenylpiperidine, 4-phenyl-1,2,3,6-tetrahydropyridine, or 4-phenylpiperazine compounds or dimeric spirocyclic piperidine compounds having general formula (I), ##STR1## wherein n is 1-5; R.sup.1 to R.sup.4 are substituents; R.sup.5 and R.sup.6 each hydrogen or alkyl or form together an ethylene or propylene bridge; X is O, S, SO, SO.sub.2, CO or (CH.sub.2).sub.m, m being 0 or 1, X is NR.sup.7, R.sup.7 being H, alkyl, cycloalkyl, cycloalkylalkyl, phenyl, or phenylalkyl, or X is CR.sup.8 R.sup.9, wherein R.sup.8 and R.sup.9 are selected from hydroxy and the substituents defined under R.sup.7 ; and (i) Z.sup.1 is a substituent and Z.sup.2 is (CH.sub.2).sub.p wherein p is 0; and Y is N, C or CH; (ii) Z.sup.1 and Y are linked together via a single bond, thereby forming a spirocyclic junction; in which case Y is C; Z.sup.1 is O, S, (CH.sub.2).sub.q, q being 1, 2 or 3, or Z.sup.1 is CH.sub.2 O, CH.sub.2 S, CH.sub.2 CH.sub.2 O, CH.sub.2 CH.sub.2 S, CH.dbd.CH, CH.dbd.CHCH.sub.2, CH.sub.2 OCH.sub.2, CH.sub.2 SCH.sub.2, CH.dbd.CH--O, or CH.dbd.CH--S; and Z.sup.2 is O, S or (CH.sub.2).sub.p, p being 0 or 1; are potent sigma receptor ligands thus being useful as drugs for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile demential of the Alzheimer type or Parkinson's disease.
摘要翻译： 本发明涉及具有通式（I）的二聚4-苯基哌啶，4-苯基-1,2,3,6-四氢吡啶或4-苯基哌嗪化合物或二聚螺环哌啶化合物，其中 n为1-5; R1至R4是取代基; R5和R6各自为氢或烷基或一起形成乙烯或丙烯桥; X是O，S，SO，SO2，CO或（CH2）m，m是0或1，X是NR7，R7是H，烷基，环烷基，环烷基烷基，苯基或苯基烷基，或X是CR8R9，其中R8和 R9选自羟基和R7定义的取代基; 和（i）Z1是取代基，Z2是（CH2）p，其中p是0; Y为N，C或CH; （ii）Z1和Y通过单键连接在一起，从而形成螺环结; 在这种情况下，Y是C; Z1是O，S，（CH2）q，q是1,2或3，或Z1是CH2O，CH2S，CH2CH2O，CH2CH2S，CH = CH，CH = CHCH2，CH2OCH2，CH2SCH2，CH = CH-O或CH = CH-S; Z2为O，S或（CH2）p，p为0或1; 是有效的西格玛受体配体，因此可用作治疗焦虑，精神病，癫痫，惊厥，运动障碍，运动障碍，遗忘症，脑血管疾病，阿尔茨海默氏型老年痴呆症或帕金森病的药物。
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.024 秒)
